NEW METHOD OF PHARMACOLOGICAL CORRECTION OF POST-HYPOXIC CARDIOPATHY IN NEWBORNS

Abstract

Early diagnosis and timely correction of pathological changes in the newborns’ heart can be a major factor in reducing the frequency and severity of cardiovascular pathology in older children and adults. Given the important role of secondary carnitine deficiency in developing disadaptant cardiopathies in newborns (especially premature and immature), the study of the efficacy of exogenous levocarnitine (L-carnitine) in neonatal cardiology offers the greatest promise. The study was aimed at evaluating the efficacy of L-carnitine solution in the post-hypoxic syndrome of cardiovascular deconditioning in newborns, including premature infants. After the treatment course, the newborns showed the effective reduction of signs of electrical instability and myocardial ischemia, restoration of heart rate and resetting of systolic and diastolic function of the heart, the size of the heart cavities, a decrease in the diameter and hemodynamic significance of functioning fetal communications, the restoration of the circadian heart rhythm profile, as well as a reduction in the duration of pauses in rhythm and arrhythmias. The study results showed the efficacy and safety of the L-carnitine solution in correcting cardiac disorders in newborns with hypoxic myocardial damage.

Keywords

• newborns
• post-hypoxic cardiopathy
• l-carnitine
• hypoxia